Response to raise Canadian$1.5m in private funds:
This article was originally published in Clinica
Executive Summary
Canadian diagnostics developer Response Biomedical is issuing up to 1,875,000 new shares, at Can$0.80 ($0.67) each, through Haywood Securities. Proceeds from the Can$1.5m private placement will go towards enhancing the Vancouver-based company's sales operations, scaling up its manufacturing capacity and accelerating new product development opportunities through its RAMP rapid, on-site diagnostic platform.